Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus S1 maintenance in pancreatic cancer
NCT02945267Phase 4Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2016
- Primary completion
- Dec 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in pancreatic cancer (PC) comparing Nimotuzumab + S1 with Placebo + S1 (2 arms). Primary endpoint: Time to Progression at 3 years. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02945267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02945267.